ptd-dbm
CXXC5 DECOY PEPTIDE · WNT/BETA-CATENIN ACTIVATOR · TOPICAL · MOUSE-ONLY
also: PTD-DBM · PTD-DBM peptide · protein transduction domain-Dishevelled binding motif
PTD-DBM is a fusion peptide combining a cell-penetrating protein transduction domain with the Dishevelled-binding motif of CXXC5, a negative regulator of Wnt/beta-catenin signalling. Acting as a decoy, it is intended to occupy Dishevelled and prevent CXXC5 from binding it, thereby de-repressing Wnt signalling in skin; in mice, topical application accelerates hair regrowth and wound-induced hair follicle neogenesis. All published work is preclinical, topical and from a single Korean laboratory; there are no human data and no registered clinical trial.
// our evidence grade — unedited
A ClinicalTrials.gov search for PTD-DBM returns zero registered studies, and there is no published human experiment of any kind — not a case series, not a pilot, not an ex vivo human scalp study using the peptide. Every PTD-DBM paper comes from Kang-Yell Choi's laboratory at Yonsei University, every in vivo experiment is topical application to mouse skin, and the group's own trajectory has been to abandon the peptide in favour of small molecules (KY19382, KY19334).
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | PTD-DBM — a protein-transduction-domain-fused Dishevelled-binding motif peptide derived from CXXC5, used as a decoy to disrupt the CXXC5-Dishevelled interaction |
| purity | ≥ 98% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Lyophilised powder is stored desiccated at -20 °C and protected from light. Once reconstituted, laboratory practice is refrigeration at 2-8 °C for short-term use, or aliquoting and freezing to avoid repeated freeze-thaw cycles. Handling information only; this material has no approved human use. |
| solubility | Short hydrophilic peptide, readily soluble in sterile or bacteriostatic water and in dilute aqueous buffer. Lot-specific solubility is stated on the certificate of analysis. |
| sequence | Not disclosed in any of the peer-reviewed papers. The originating group's own patent (US20150224167A1, Yonsei University; inventors Kang-Yell Choi, Soung-Hoon Lee, Hyun-Yi Kim) claims the construct as SEQ ID NO:7, RRRRRRRRGGGGRKTGHQICKFRKC — an octa-arginine protein-transduction domain, a tetraglycine linker, and the Dishevelled-binding motif RKTGHQICKFRKC, which corresponds exactly to residues 284-296 of human CXXC5 (UniProt Q7LFL8). Material sold under the name PTD-DBM has not been shown to correspond to this construct, and other protein-transduction domains (HIV-Tat, Antp, transportan, VP22) are claimed as alternatives in the same patent. |
// select size
crypto payment · research use only · not for human consumption
// others in Cosmetic